Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00054595.xml
Download PDF
CC BY 4.0 · Arq Neuropsiquiatr 2025; 83(07): s00451809664
DOI: 10.1055/s-0045-1809664
DOI: 10.1055/s-0045-1809664
Review Article
A diagnostic approach to neurocutaneous syndromes
Abstract
Neurocutaneous syndromes are a group of genetically and phenotypically diverse disorders that primarily affect the skin, central and peripheral nervous systems, and eyes. Classifying neurocutaneous syndromes based on genetic mechanisms often proves impractical in routine clinical settings. This review proposes a practical classification of neurocutaneous syndromes based on their neurological manifestations, including neoplastic lesions, epilepsy, vascular abnormalities, and ataxia. In this narrative review, we examined original articles and reviews that explore neurocutaneous syndromes, published between January 2000 and July 2024. The figures are part of a personal collection of the authors. Early recognition of dermatological and neurological hallmarks can guide diagnosis and prompt timely evaluation and treatment. Therefore, a thorough understanding of neurocutaneous syndromes highlights the importance of integrated diagnostic strategies that combine neurological and dermatological assessments.
Authors' Contributions
Conceptualization: SMG, JVGT, MPMM, TYTS, JLP, OGPB; Methodology: SMG, JVGT, JLP, OGPB; Project administration: JLP, OGPB; Writing – original draft: SMG, JVGT; Writing – review & editing: MPMM, TYTS, FTL, JLP, OGPB.
Data Statement Availability
Data are available on demand.
Editor-in-Chief: Hélio A. G. Teive https://orcid.org/0000-0003-2305-1073.
Associate Editor: Eduardo Genaro Mutarelli https://orcid.org/0000-0003-3859-4150.
Publication History
Received: 23 December 2024
Accepted: 13 April 2025
Article published online:
25 June 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua Rego Freitas, 175, loja 1, República, São Paulo, SP, CEP 01220-010, Brazil
Bibliographical Record
Sofia Mônaco Gama, João Vitor Gerdulli Tamanini, Marianna Pinheiro Moraes de Moraes, Thiago Yoshinaga Tonholo Silva, Fernanda Teresa de Lima, José Luiz Pedroso, Orlando Graziani Povoas Barsottini. A diagnostic approach to neurocutaneous syndromes. Arq Neuropsiquiatr 2025; 83: s00451809664.
DOI: 10.1055/s-0045-1809664
Sofia Mônaco Gama, João Vitor Gerdulli Tamanini, Marianna Pinheiro Moraes de Moraes, Thiago Yoshinaga Tonholo Silva, Fernanda Teresa de Lima, José Luiz Pedroso, Orlando Graziani Povoas Barsottini. A diagnostic approach to neurocutaneous syndromes. Arq Neuropsiquiatr 2025; 83: s00451809664.
DOI: 10.1055/s-0045-1809664
-
References
- 1 Klar N, Cohen B, Lin DDM. Neurocutaneous syndromes. Handb Clin Neurol 2016; 135: 565-589
- 2 Rosser T. Neurocutaneous Disorders. Continuum (Minneap Minn) 2018; 24 (1, Child Neurology): 96-129
- 3 Gutmann DH, Ferner RE, Listernick RH, Korf BR, Wolters PL, Johnson KJ. Neurofibromatosis type 1. Nat Rev Dis Primers 2017; 3: 17004
- 4 Bajenaru ML, Hernandez MR, Perry A, Zhu Y, Parada LF, Garbow JR, Gutmann DH. Optic nerve glioma in mice requires astrocyte Nf1 gene inactivation and Nf1 brain heterozygosity. Cancer Res 2003; 63 (24) 8573-8577
- 5 Marco SBS, Pisón JL, Escribano CC, Viejo IG, Gallart MDM, Villagrasa PS. Neurological manifestations of neurofibromatosis type 1: our experience. Neurologia (Engl Ed) 2022; 37 (05) 325-333
- 6 Bayat M, Bayat A. Neurological manifestations of neurofibromatosis: a review. Neurol Sci 2020; 41 (10) 2685-2690
- 7 De Schepper S, Maertens O, Callens T, Naeyaert JM, Lambert J, Messiaen L. Somatic mutation analysis in NF1 café au lait spots reveals two NF1 hits in the melanocytes. J Invest Dermatol 2008; 128 (04) 1050-1053
- 8 Di Pietro S, Reali L, Tona E, Belfiore G, Praticò AD, Ruggieri M. et al Magnetic Resonance Imaging of Central Nervous System Manifestations of Type 1 Neurofibromatosis: Pictorial Review and Retrospective Study of Their Frequency in a Cohort of Patients. J Clin Med 2024; 13 (11) 3311
- 9 Hainc N, Wagner MW, Laughlin S, Rutka J, Hawkins C, Blaser S, Ertl-Wagner BB. et al Longitudinal Assessment of Enhancing Foci of Abnormal Signal Intensity in Neurofibromatosis Type 1. AJNR Am J Neuroradiol 2021; 42 (04) 766-773
- 10 Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y. et al; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC). Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med 2021; 23 (08) 1506-1513
- 11 Ferner RE, Huson SM, Thomas N, Moss C, Willshaw H, Gareth Evans D. et al Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet 2007; 44 (02) 81-88
- 12 No authors listed. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med 2020; 383 (13) 1290-1290 10.1056/NEJMx200013 Erratum for: N Engl J Med 2020;382(15):1430–1442.
- 13 Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR. Neurofibromatosis type 2. Lancet 2009; 373 (9679) 1974-1986
- 14 Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S. Correction to: An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol 2020; 139 (04) 667-667
- 15 Armentano M, Lucchino L, Alisi L, Chicca AV, Di Martino V, Miraglia E. et al Ophthalmic Manifestation in Neurofibromatosis Type 2. Appl Sci (Basel) 2023; 13 (10) 6304 10.3390/app13106304
- 16 Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO. et al; International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC). Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genet Med 2022; 24 (09) 1967-1977
- 17 Plotkin SR, Yohay KH, Nghiemphu PL, Dinh CT, Babovic-Vuksanovic D, Merker VL. et al; INTUITT-NF2 Consortium. Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors. N Engl J Med 2024; 390 (24) 2284-2294
- 18 Portocarrero LKL, Quental KN, Samorano LP, Oliveira ZNPd, Rivitti-Machado MCdM. Tuberous sclerosis complex: review based on new diagnostic criteria. An Bras Dermatol 2018; 93 (03) 323-331
- 19 Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372 (9639) 657-668
- 20 Lu DS, Karas PJ, Krueger DA, Weiner HL. Central nervous system manifestations of tuberous sclerosis complex. Am J Med Genet C Semin Med Genet 2018; 178 (03) 291-298 10.1002/ajmg.c.31647
- 21 Henske EP, Jóźwiak S, Kingswood JC, Sampson JR, Thiele EA. Tuberous sclerosis complex. Nat Rev Dis Primers 2016; 2: 16035
- 22 Northrup H, Krueger DA. International Tuberous Sclerosis Complex Consensus Group. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational Tuberous Sclerosis Complex Consensus Conference. Pediatr Neurol 2013; 49 (04) 243-254
- 23 Von Ranke FM, Faria IM, Zanetti G, Hochhegger B, Souza Jr AS, Marchiori E. Imaging of tuberous sclerosis complex: a pictorial review. Radiol Bras 2017; 50 (01) 48-54
- 24 Varshney N, Kebede AA, Owusu-Dapaah H, Lather J, Kaushik M, Bhullar JS. A Review of Von Hippel-Lindau Syndrome. J Kidney Cancer VHL 2017; 4 (03) 20-29
- 25 Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet 2011; 19 (06) 617-623
- 26 Matsusue E, Inoue C, Tabuchi S, Yoshioka H, Nagao Y, Matsumoto K. et al Advanced magnetic resonance imaging findings of cerebellar hemangioblastomas: A report of three cases and a literature review. Acta Radiol Open 2022; 11 (02) 20 584601221077074.
- 27 Binderup MLM, Smerdel M, Borgwadt L, Nielsen SSB, Madsen MG, Møller HU. et al von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance. Eur J Med Genet 2022; 65 (08) 104538
- 28 Miraglia E, Laghi A, Iacovino C, Moramarco A, Giustini S. Gorlin-Goltz Syndrome: clinical findings in the Italian population. Ital J Dermatol Venereol 2022; 157 (01) 101-102
- 29 Jawa DS, Sircar K, Somani R, Grover N, Jaidka S, Singh S. Gorlin-Goltz syndrome. J Oral Maxillofac Pathol 2009; 13 (02) 89-92
- 30 Hasan A, Akintola D. An Update of Gorlin-Goltz Syndrome. Prim Dent J 2018; 7 (03) 38-41
- 31 Oliveira GdP, Soares NLR, Araújo RL, Dutra LA, Pedroso JL, Barsottini OGP. Teaching Neuro Images: Clinical and neuroimaging features in Gorlin-Goltz syndrome. Neurology 2017; 88 (07) e53-e54
- 32 Shetty SK, Doddawad VG, Sundar S, Shivananda S. Exploring the Changing Diagnostic Criteria of Gorlin-Goltz Syndrome: A Case Report. Oncology (Williston Park) 2023; 37 (11) 449-554
- 33 Islam MP. Neurocutaneous melanosis. Handb Clin Neurol 2015; 132: 111-117
- 34 Ream M. Hypomelanosis of Ito. Handb Clin Neurol 2015; 132: 281-289
- 35 Koen N, Fourie J, Terburg D, Stoop R, Morgan B, Stein DJ, van Honk J. et al Translational neuroscience of basolateral amygdala lesions: Studies of Urbach-Wiethe disease. J Neurosci Res 2016; 94 (06) 504-512
- 36 Kinsler VA, Thomas AC, Ishida M, Bulstrode NW, Loughlin S, Hing S. et al Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol 2013; 133 (09) 2229-2236
- 37 Fledderus AC, Widdershoven AL, Lapid O, Breugem CC, Pasmans SGMA, van der Horst CMAM. et al Neurological signs, symptoms and MRI abnormalities in patients with congenital melanocytic naevi and evaluation of routine MRI-screening: systematic review and meta-analysis. Orphanet J Rare Dis 2022; 17 (01) 95
- 38 Scattolin MAA, Lin J, Peruchi MM, Rocha AJ, Masruha MR, Vilanova LCP. Neurocutaneous melanosis: follow-up and literature review. J Neuroradiol 2011; 38 (05) 313-318
- 39 Ruggieri M, Polizzi A, Catanzaro S, Bianco ML, Praticò AD, Di Rocco C. Neurocutaneous melanocytosis (melanosis). Childs Nerv Syst 2020; 36 (10) 2571-2596
- 40 Moreira BL, Grunewald T, Côrtes AAJ, Marussi VHR, Amaral LLFd. Neurocutaneous melanosis. Radiol Bras 2016; 49 (06) 412-413
- 41 Küster W, König A. Hypomelanosis of Ito: no entity, but a cutaneous sign of mosaicism. Am J Med Genet 1999; 85 (04) 346-350
- 42 Ruiz-Maldonado R, Toussaint S, Tamayo L, Laterza A, Del Castillo V. Hypomelanosis of Ito: diagnostic criteria and report of 41 cases. Pediatr Dermatol 1992; 9 (01) 1-10
- 43 Assogba K, Ferlazzo E, Striano P, Calarese T, Villeneuve N, Ivanov I. et al Heterogeneous seizure manifestations in Hypomelanosis of Ito: report of four new cases and review of the literature. Neurol Sci 2010; 31 (01) 9-16
- 44 Souza PV, Pinto Wde R, Calente FG, Burlin S, Pedroso JL, Oliveira ASB, Barsottini OGP. Hypomelanosis of Ito presenting with adult-onset dementia and marked enlarged Virchow-Robin spaces. Arq Neuropsiquiatr 2015; 73 (04) 366-368
- 45 Yu DA, Kwon O, Kim KH. Hypomelanosis of Ito with Multiple Congenital Anomalies. Ann Dermatol 2019; 31 (05) 576-580
- 46 Quirici MB, da Rocha AJ. Teaching NeuroImages: lipoid proteinosis (Urbach-Wiethe disease): typical findings in this rare genodermatosis. Neurology 2013; 80 (09) e93
- 47 Gonçalves FG, Melo MBd, Matos VdL, Barra FR, Figueroa RE. Amygdalae and striatum calcification in lipoid proteinosis. AJNR Am J Neuroradiol 2010; 31 (01) 88-90 10.3174/ajnr.A1699
- 48 Akarsu EO, Dinçsoy Bir F, Baykal C, Taşdemir V, Kara B, Bebek N. et al The Characteristics and Long-Term Course of Epilepsy in Lipoid Proteinosis: A Spectrum From Mild to Severe Seizures in Relation to ECM1 Mutations. Clin EEG Neurosci 2018; 49 (03) 192-196
- 49 Chew APT, Gupta G, Alatakis S, Schneider-Kolsky M, Stuckey SL. Hippocampal calcification prevalence at CT: a retrospective review. Radiology 2012; 265 (02) 504-510
- 50 Tamanini JVG, Inoue Y, Cardoso TAMdO, Reis F. Sturge-Weber Syndrome and Hippocampal Sclerosis: Two Epileptogenic Conditions in One Patient. Neurol India 2023; 71 (05) 1090-1091
- 51 Higueros E, Roe E, Granell E, Baselga E. Sturge-Weber Syndrome: A Review. Actas Dermosifiliogr 2017; 108 (05) 407-417
- 52 Ch'ng S, Tan ST. Facial port-wine stains - clinical stratification and risks of neuro-ocular involvement. J Plast Reconstr Aesthet Surg 2008; 61 (08) 889-893
- 53 Valery CB, Comi AM. Sturge–Weber syndrome: Updates in pathogenesis, diagnosis, and treatment. Ann Child Neurol Soc 2023; 1 (03) 186-201
- 54 Abdolrahimzadeh S, Scavella V, Felli L, Cruciani F, Contestabile MT, Recupero SM. Ophthalmic Alterations in the Sturge-Weber Syndrome, Klippel-Trenaunay Syndrome, and the Phakomatosis Pigmentovascularis: An Independent Group of Conditions?. BioMed Res Int 2015; 2015: 786519
- 55 Sabeti S, Ball KL, Burkhart C, Eichenfield L, Faith EF, Frieden IJ. et al Consensus Statement for the Management and Treatment of Port-Wine Birthmarks in Sturge-Weber Syndrome. JAMA Dermatol 2021; 157 (01) 98-104
- 56 Yeom S, Comi AM. Updates on Sturge-Weber Syndrome. Stroke 2022; 53 (12) 3769-3779
- 57 McDonald J, Bayrak-Toydemir P, Pyeritz RE. Hereditary hemorrhagic telangiectasia: an overview of diagnosis, management, and pathogenesis. Genet Med 2011; 13 (07) 607-616
- 58 Faughnan ME, Mager JJ, Hetts SW, Palda VA, Lang-Robertson K, Buscarini E. et al Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia. Ann Intern Med 2020; 173 (12) 989-1001
- 59 Bayrak-Toydemir P, Mao R, Lewin S, McDonald J. Hereditary hemorrhagic telangiectasia: an overview of diagnosis and management in the molecular era for clinicians. Genet Med 2004; 6 (04) 175-191
- 60 Berg J, Porteous M, Reinhardt D, Gallione C, Holloway S, Umasunthar T. et al Hereditary haemorrhagic telangiectasia: a questionnaire based study to delineate the different phenotypes caused by endoglin and ALK1 mutations. J Med Genet 2003; 40 (08) 585-590
- 61 Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Westermann CJ. et al Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000; 91 (01) 66-67
- 62 Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet J Rare Dis 2016; 11 (01) 159
- 63 Amirifar P, Ranjouri MR, Lavin M, Abolhassani H, Yazdani R, Aghamohammadi A. Ataxia-telangiectasia: epidemiology, pathogenesis, clinical phenotype, diagnosis, prognosis and management. Expert Rev Clin Immunol 2020; 16 (09) 859-871
- 64 Amirifar P, Ranjouri MR, Yazdani R, Abolhassani H, Aghamohammadi A. Ataxia-telangiectasia: A review of clinical features and molecular pathology. Pediatr Allergy Immunol 2019; 30 (03) 277-288
- 65 Sahama I, Sinclair K, Pannek K, Lavin M, Rose S. Radiological imaging in ataxia telangiectasia: a review. Cerebellum 2014; 13 (04) 521-530
- 66 Ribeiro RM, Vasconcelos SC, Lima PLGSB, Coelho EF, Oliveira AMN, Gomes EdABM. et al Pathophysiology and Treatment of Lipid Abnormalities in Cerebrotendinous Xanthomatosis: An Integrative Review. Brain Sci 2023; 13 (07) 979
- 67 Islam M, Hoggard N, Hadjivassiliou M. Cerebrotendinous Xanthomatosis: diversity of presentation and refining treatment with chenodeoxycholic acid. Cerebellum Ataxias 2021; 8 (01) 5
- 68 Nóbrega PR, Bernardes AM, Ribeiro RM, Vasconcelos SC, Araújo DABS, Gama VCdV. et al Cerebrotendinous Xanthomatosis: A practice review of pathophysiology, diagnosis, and treatment. Front Neurol 2022; 13: 1049850
- 69 Moghadasian MH, Salen G, Frohlich JJ, Scudamore CH. Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch Neurol 2002; 59 (04) 527-529
- 70 Barkhof F, Verrips A, Wesseling P, van Der Knaap MS, van Engelen BG, Gabreëls FJ. et al Cerebrotendinous xanthomatosis: the spectrum of imaging findings and the correlation with neuropathologic findings. Radiology 2000; 217 (03) 869-876